Stock events for Ekso Bionics Holdings, Inc. (EKSO)
Several events impacted EKSO's stock price in the past six months. The company reported revenue growth of 2% year-over-year and a 105% sequential rebound to $4.2 million in Q3 2025. Ekso Bionics announced a $3.7 million registered direct offering of common stock. Ekso Bionics inked an agreement to become the exclusive U.S. distributor for MediTouch's BalanceTutor™ Rehabilitation System. The company priced a private placement to sell 5,852 shares of Series B preferred stock and warrants to buy up to 355,960 common shares. A proposed merger with a cloud computing business from Applied Digital was announced. Full year 2025 earnings, including Q4, reportedly missed analyst expectations. EKSO's share price has been volatile over the past three months compared to the U.S. market.
Demand Seasonality affecting Ekso Bionics Holdings, Inc.’s stock price
Demand for Ekso Bionics' products and services appears to have some seasonality, particularly within its Enterprise Health segment. Capital budget impact from certain inpatient rehabilitation facilities led to a revenue decline in Q1 2025. The Personal Health product line, driven by the Ekso Indego Personal device, demonstrated strong growth. The establishment of CMS pricing determination for the Indego Personal Exoskeleton in Q2 2024 is expected to create a significant market opportunity.
Overview of Ekso Bionics Holdings, Inc.’s business
Ekso Bionics Holdings, Inc. develops and manufactures powered exoskeleton bionic devices for healthcare and industrial markets. The company operates in the Health Technology sector, specifically in Medical Specialties or Medical - Instruments & Supplies, and is segmented into Enterprise Health and Personal Health. Key products include EksoNR for rehabilitation, Ekso Indego Therapy for rehabilitation settings, Ekso Indego Personal for personal use by individuals with spinal cord injuries, Ekso EVO for industrial workers, Ekso Nomad, MediTouch BalanceTutor™ Rehabilitation System, and EksoCare.
EKSO’s Geographic footprint
Ekso Bionics Holdings, Inc. conducts all its operations within the United States, with its corporate office located in San Rafael, California. The company serves customers across the Americas, EMEA (Europe, Middle East, and Africa), and APAC (Asia-Pacific) regions, including Germany.
EKSO Corporate Image Assessment
Ekso Bionics has a history of recognition, including being selected as Wired magazine's number two "Most Significant Gadget of 2010". Ekso Bionics was accepted into the NVIDIA Connect program, supporting its strategic initiative to build a proprietary foundation model for human motion and integrate AI capabilities into its exoskeleton devices. Ekso Bionics announced an initial proof-of-concept for an AI voice agent ("Ekso Voice Agent") for intelligent control of its EksoNR device. The company launched eksoUniversity, a virtual platform offering continuing education courses. Ekso Bionics launched its new software, GaitCoach, providing more guidance to therapists. The company has a history of operating losses, with a deficit of over $262 million since its founding. The announced merger with Applied Digital (ChronoScale Corporation) in February 2026, which would dilute existing shareholders by 97%, could be perceived negatively by investors.
Ownership
Ekso Bionics Holdings, Inc. has 29 institutional owners and shareholders. Institutional ownership accounts for approximately 16.2% of the company, while individual investors hold about 20.5%. Major institutional owners include Vanguard Group Inc., Geode Capital Management, LLC, and BlackRock, Inc.
